Drug Trial Radar · NCT06232252
A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
May 6, 2024
Primary completion
Apr 25, 2025
Study completion Apr 29, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 765423 in healthy male subjects.
Conditions
- Healthy
Interventions
BI 765423Drug
BI 765423
Placebo matching BI 765423Drug
Placebo matching BI 765423
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects treated with BI 765423 who experience any treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: up to 145 days for DG 1 and 2, up to 159 days for DG 3 and 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Life Science Services - Clinical Research
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.